Home › Funds › PRIMECAP MANAGEMENT CO/CA/ › BMRN
PRIMECAP MANAGEMENT CO/CA/ position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
PRIMECAP MANAGEMENT CO/CA/ reported holding 14,988,996 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$899.3M, representing 0.56% of its reported portfolio and ranking #45 among its reported holdings. PRIMECAP MANAGEMENT CO/CA/ has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How PRIMECAP MANAGEMENT CO/CA/'s BMRN position evolved
PRIMECAP MANAGEMENT CO/CA/ first disclosed a stake in BMRN in Q3 2023 at 18,406,539 shares (US$1.63B). The position peaked in Q4 2023 at 18,414,374 shares, worth US$1.78B. Across 13 filings, PRIMECAP MANAGEMENT CO/CA/ increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 14,988,996 shares valued at US$899.3M — an increase of 798,813 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 18.41M | $1.63B | New |
| Q4 2023 | 18.41M | $1.78B | Hold |
| Q1 2024 | 18.71M | $1.63B | Add |
| Q2 2024 | 18.79M | $1.55B | Hold |
| Q3 2024 | 18.87M | $1.33B | Hold |
| Q4 2024 | 18.19M | $1.20B | Reduce |
| Q1 2025 | 17.77M | $1.26B | Reduce |
| Q2 2025 | 15.77M | $867.00M | Reduce |
| Q3 2025 | 15.23M | $824.82M | Reduce |
| Q4 2025 | 14.55M | $864.67M | Reduce |
| Q1 2026 | 14.19M | $801.82M | Reduce |
| Q2 2026 | 14.19M | $811.96M | Hold |
| Q3 2026 | 14.99M | $899.34M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 25 other funds we track also report a position in BMRN — the largest reported positions include Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M), Vestal Point Capital, LP (US$344.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on PRIMECAP MANAGEMENT CO/CA/
FAQ
How long has PRIMECAP MANAGEMENT CO/CA/ held BMRN?
PRIMECAP MANAGEMENT CO/CA/ has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is PRIMECAP MANAGEMENT CO/CA/'s current position in BMRN?
As of Q3 2026, PRIMECAP MANAGEMENT CO/CA/ holds 14.99M shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $899.34M, representing 0.56% of its reported portfolio and ranking #45.
Has PRIMECAP MANAGEMENT CO/CA/ been buying or selling BMRN?
In the latest 13F filing (Q3 2026), PRIMECAP MANAGEMENT CO/CA/ increased its position in BMRN. The position peaked in Q4 2023 at 18.41M shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include Viking Global Investors, VIKING GLOBAL INVESTORS LP, Vestal Point Capital, LP, among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.